Cg Oncology Inc (CGON)

$53.09 +2.01 (3.94%)
Market Cap 4.12B
Revenue (ttm) 1.14M
Net Income (ttm) -88.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,722.81%
Debt to Equity Ratio 0.00
Volume 1,139,000
Avg Vol 1,113,882
Day's Range N/A - N/A
Shares Out 80.67M
Stochastic %K 64%
Beta 1.31
Analysts Strong Sell
Price Target $79.21

Company Profile

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC p...

Industry: Biotechnology
Sector: Healthcare
Phone: 949 409 3700
Address:
400 Spectrum Center Drive, Suite 2040, Irvine, United States
thewavetrading
thewavetrading Feb. 11 at 2:21 AM
$CGON has formed a bullish flag. I would take a long position with a stop below today's low.
0 · Reply
Quantumup
Quantumup Feb. 10 at 7:35 PM
Truist⬆️ $CGON's PT to $75 and reiterated at a Buy rating. $URGN JNJ $IBRX MRK $TARA PFE $TYRA Here's what Truist said: CGON is set to disclose PIVOT-006 topline in IR NMIBC in 1H26 - a setting with a large addressable market & less competition where Creto is the most advanced candidate with broad disease coverage (LG/HG Ta, including newly diagnosed patients). Here, we provide a mini-primer on the IR NMIBC landscape, and PIVOT-006's setup against our efficacy bars (HR, 12-mos RFS). We see a potential for -/+30% stock move, & assign a 55% PoS to our Good/Best-case scenarios (PoS-adj 6% upside potential). Ahead of data and following our market analysis, we fine-tune our model, lifting peak sales in IR NMIBC to $1.8B (from $1.4B), and increase our PT to $75 (from $66) - Reiterate Buy.
0 · Reply
Grinding10
Grinding10 Feb. 10 at 6:56 PM
$CGON can u ever hold a fucking gain🤷‍♂️
0 · Reply
Buy_SoFi
Buy_SoFi Feb. 9 at 3:39 PM
$TLTFF <------ This one will surprise everyone one of these days with an Accelerated Approval out of nowhere. $IBRX $CGON $NVO Should also trade on NASDAQ by EoY. $XBI
0 · Reply
Buy_SoFi
Buy_SoFi Feb. 4 at 6:38 PM
$TLTFF Updated numbers just came out. Getting better and better. Pressure and momentum building up, about to blow up. $CGON $IBRX Get in and multi bag
0 · Reply
SilverEagle
SilverEagle Feb. 4 at 1:35 PM
$CGON good looking bio 👀
0 · Reply
BIgBill374
BIgBill374 Feb. 3 at 10:07 PM
$CGON
0 · Reply
PhantomZ
PhantomZ Feb. 2 at 5:53 PM
$TLTFF $IBRX $CGON Highly undervalued at $50 Million MC 10 bagger just to start.iMO One and Done NMIBC treatment with high efficacy.. 90 patients treated and enrolment completed. Possible FDA Health Canada AA submission very soon as Full data on 76+ patients ready. IMO do your DD https://www.theglobeandmail.com/investing/markets/markets-news/Newsfile/37355900/theralaser-completes-enrollment-in-bladder-cancer-clinical-study/
1 · Reply
PhantomZ
PhantomZ Feb. 2 at 5:51 PM
$TLTFF $IBRX $CGON Highly undervalued at $50 Million MC 10 bagger just to start.iMO One and Done NMIBC treatment with high efficacy.. 90 patients treated and enrolment completed. Possible FDA Health Canada AA submission very soon as Full data on 76+ patients ready. IMO do your DD
1 · Reply
BIgBill374
BIgBill374 Jan. 28 at 4:04 PM
$CGON
1 · Reply
Latest News on CGON
CG Oncology, Inc. (CGON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 15, 2026, 3:15 PM EST - 26 days ago

CG Oncology, Inc. (CGON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene

Jan 11, 2026, 8:30 AM EST - 4 weeks ago

CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene

CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC

Jan 9, 2026, 8:30 AM EST - 4 weeks ago

CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC

CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 8:00 AM EST - 5 weeks ago

CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

CG Oncology Undervalued Going Into A Busy 2026

Dec 23, 2025, 4:43 AM EST - 7 weeks ago

CG Oncology Undervalued Going Into A Busy 2026

New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer

Dec 5, 2025, 8:30 AM EST - 2 months ago

New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer

CG Oncology Announces New Board Member and Board Transition

Nov 26, 2025, 7:00 AM EST - 2 months ago

CG Oncology Announces New Board Member and Board Transition

CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 14, 2025, 8:00 AM EST - 3 months ago

CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates

CG Oncology: Upgraded, Rising, But Should We Still Be Optimistic?

Oct 9, 2025, 3:48 PM EDT - 4 months ago

CG Oncology: Upgraded, Rising, But Should We Still Be Optimistic?

CG Oncology, Inc. (CGON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 9, 2025, 10:31 AM EDT - 5 months ago

CG Oncology, Inc. (CGON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

CG Oncology Stock Signals Bullish Momentum Ahead

Sep 8, 2025, 9:08 AM EDT - 5 months ago

CG Oncology Stock Signals Bullish Momentum Ahead

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

Sep 5, 2025, 7:00 AM EDT - 5 months ago

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

CG Oncology Completes Enrollment in PIVOT-006

Sep 3, 2025, 8:00 AM EDT - 5 months ago

CG Oncology Completes Enrollment in PIVOT-006

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 8, 2025, 8:00 AM EDT - 6 months ago

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)

Jun 23, 2025, 9:58 AM EDT - 8 months ago

CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 8:00 AM EDT - 8 months ago

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

May 13, 2025, 8:00 AM EDT - 9 months ago

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

Apr 28, 2025, 11:14 AM EDT - 10 months ago

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

Apr 26, 2025, 4:10 PM EDT - 10 months ago

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

CG Oncology Looks Attractive At Current Prices (Rating Upgrade)

Apr 2, 2025, 12:32 PM EDT - 11 months ago

CG Oncology Looks Attractive At Current Prices (Rating Upgrade)

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

Mar 24, 2025, 8:00 AM EDT - 11 months ago

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 1 year ago

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 16, 2024, 4:05 PM EST - 1 year ago

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene

Dec 13, 2024, 2:09 PM EST - 1 year ago

CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene

CG Oncology Announces Pricing of Public Offering

Dec 12, 2024, 8:19 PM EST - 1 year ago

CG Oncology Announces Pricing of Public Offering

CG Oncology Announces Proposed Public Offering

Dec 11, 2024, 6:17 AM EST - 1 year ago

CG Oncology Announces Proposed Public Offering

Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer

Dec 6, 2024, 1:18 PM EST - 1 year ago

Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Dec 6, 2024, 8:00 AM EST - 1 year ago

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Dec 5, 2024, 7:00 AM EST - 1 year ago

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 30, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

CG Oncology: Promising Data, But Looks Expensive

Aug 26, 2024, 10:34 AM EDT - 1 year ago

CG Oncology: Promising Data, But Looks Expensive

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 8, 2024, 8:23 AM EDT - 1 year ago

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

CG Oncology Bringing Undervalued Innovation To Bladder Cancer

Jul 9, 2024, 9:19 AM EDT - 1 year ago

CG Oncology Bringing Undervalued Innovation To Bladder Cancer

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

Jun 6, 2024, 12:14 PM EDT - 1 year ago

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

May 24, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

May 9, 2024, 8:00 AM EDT - 1 year ago

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value

May 6, 2024, 1:04 PM EDT - 1 year ago

CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

May 3, 2024, 11:23 AM EDT - 1 year ago

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

Apr 26, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

Apr 24, 2024, 10:00 AM EDT - 1 year ago

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

Mar 28, 2024, 8:00 AM EDT - 2 years ago

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

Protara: A Bombed Out Biotech With A Very Positive Skew

Feb 22, 2024, 8:55 AM EST - 2 years ago

Protara: A Bombed Out Biotech With A Very Positive Skew

TARA

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 30, 2024, 7:00 AM EST - 2 years ago

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

American Healthcare REIT, Fortegra and Fractyle Health set IPO price ranges as thaw continues

Jan 29, 2024, 8:14 AM EST - 2 years ago

American Healthcare REIT, Fortegra and Fractyle Health set IPO price ranges as thaw continues

BTSG

U.S. IPO Weekly Recap: Biotech CG Oncology Pops 96% In A 7 IPO Week

Jan 27, 2024, 1:30 AM EST - 2 years ago

U.S. IPO Weekly Recap: Biotech CG Oncology Pops 96% In A 7 IPO Week

Biotech's First IPO of 2024 Popped 96%. What It Means.

Jan 26, 2024, 11:50 AM EST - 2 years ago

Biotech's First IPO of 2024 Popped 96%. What It Means.

CG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionality

Jan 25, 2024, 2:20 PM EST - 2 years ago

CG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionality

CG Oncology valued at $1.75 bln in strong market debut

Jan 25, 2024, 1:46 PM EST - 2 years ago

CG Oncology valued at $1.75 bln in strong market debut

CG Oncology IPO prices above range and boosts share count in bullish move ahead of trading

Jan 25, 2024, 7:51 AM EST - 2 years ago

CG Oncology IPO prices above range and boosts share count in bullish move ahead of trading

CG Oncology Announces Pricing of Upsized Initial Public Offering

Jan 24, 2024, 7:10 PM EST - 2 years ago

CG Oncology Announces Pricing of Upsized Initial Public Offering

thewavetrading
thewavetrading Feb. 11 at 2:21 AM
$CGON has formed a bullish flag. I would take a long position with a stop below today's low.
0 · Reply
Quantumup
Quantumup Feb. 10 at 7:35 PM
Truist⬆️ $CGON's PT to $75 and reiterated at a Buy rating. $URGN JNJ $IBRX MRK $TARA PFE $TYRA Here's what Truist said: CGON is set to disclose PIVOT-006 topline in IR NMIBC in 1H26 - a setting with a large addressable market & less competition where Creto is the most advanced candidate with broad disease coverage (LG/HG Ta, including newly diagnosed patients). Here, we provide a mini-primer on the IR NMIBC landscape, and PIVOT-006's setup against our efficacy bars (HR, 12-mos RFS). We see a potential for -/+30% stock move, & assign a 55% PoS to our Good/Best-case scenarios (PoS-adj 6% upside potential). Ahead of data and following our market analysis, we fine-tune our model, lifting peak sales in IR NMIBC to $1.8B (from $1.4B), and increase our PT to $75 (from $66) - Reiterate Buy.
0 · Reply
Grinding10
Grinding10 Feb. 10 at 6:56 PM
$CGON can u ever hold a fucking gain🤷‍♂️
0 · Reply
Buy_SoFi
Buy_SoFi Feb. 9 at 3:39 PM
$TLTFF <------ This one will surprise everyone one of these days with an Accelerated Approval out of nowhere. $IBRX $CGON $NVO Should also trade on NASDAQ by EoY. $XBI
0 · Reply
Buy_SoFi
Buy_SoFi Feb. 4 at 6:38 PM
$TLTFF Updated numbers just came out. Getting better and better. Pressure and momentum building up, about to blow up. $CGON $IBRX Get in and multi bag
0 · Reply
SilverEagle
SilverEagle Feb. 4 at 1:35 PM
$CGON good looking bio 👀
0 · Reply
BIgBill374
BIgBill374 Feb. 3 at 10:07 PM
$CGON
0 · Reply
PhantomZ
PhantomZ Feb. 2 at 5:53 PM
$TLTFF $IBRX $CGON Highly undervalued at $50 Million MC 10 bagger just to start.iMO One and Done NMIBC treatment with high efficacy.. 90 patients treated and enrolment completed. Possible FDA Health Canada AA submission very soon as Full data on 76+ patients ready. IMO do your DD https://www.theglobeandmail.com/investing/markets/markets-news/Newsfile/37355900/theralaser-completes-enrollment-in-bladder-cancer-clinical-study/
1 · Reply
PhantomZ
PhantomZ Feb. 2 at 5:51 PM
$TLTFF $IBRX $CGON Highly undervalued at $50 Million MC 10 bagger just to start.iMO One and Done NMIBC treatment with high efficacy.. 90 patients treated and enrolment completed. Possible FDA Health Canada AA submission very soon as Full data on 76+ patients ready. IMO do your DD
1 · Reply
BIgBill374
BIgBill374 Jan. 28 at 4:04 PM
$CGON
1 · Reply
Grinding10
Grinding10 Jan. 28 at 3:22 PM
$CGON 50 cents on 1 trade 🤔makes sense
0 · Reply
lokko
lokko Jan. 27 at 1:54 PM
$CGON Volume at the top will cap this in the short term. I like the 49 or the 45 levels for a re-entry.
0 · Reply
Sw1ngb0t
Sw1ngb0t Jan. 27 at 1:39 AM
$CGON almost ready?
0 · Reply
BIgBill374
BIgBill374 Jan. 26 at 3:00 PM
$CGON fade fade fade pisses me off
1 · Reply
BioTechHealthX
BioTechHealthX Jan. 25 at 4:43 PM
$CGON CG Oncology (NASDAQ:CGON) is quietly emerging as one of the most talked-about biotech stocks in oncology. From its focused bladder cancer mission to its growing investor attention, here’s why CGON is landing on watchlists everywhere. https://biotechhealthx.com/biotech-news/is-this-the-next-breakout-biotech-why-cg-oncology-cgon-is-suddenly-on-smart-investors-radar/
0 · Reply
Grinding10
Grinding10 Jan. 23 at 8:06 PM
$CGON awesome quick $4 bucks from the high
0 · Reply
justiceforb_85
justiceforb_85 Jan. 23 at 3:34 AM
$CGON company been executing well. Look forward to holding this long-term.
1 · Reply
Grinding10
Grinding10 Jan. 22 at 5:08 PM
$CGON guess the drug stopped working
0 · Reply
dlhman2002
dlhman2002 Jan. 21 at 7:22 PM
$CGON More large scale buys today....
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 20 at 10:12 AM
$CGON Share Price: $54.66 Contract Selected: Jul 17, 2026 $55 Calls Buy Zone: $9.18 – $11.34 Target Zone: $17.26 – $21.10 Potential Upside: 78% ROI Time to Expiration: 177 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
garygb
garygb Jan. 16 at 5:55 PM
$CGON I like this.
0 · Reply
BIgBill374
BIgBill374 Jan. 16 at 5:38 PM
$CGON give me the fda approval and let’s roll see you at 78 plus
2 · Reply